[Main Financial Data](index=1&type=section&id=%E4%B8%80%E3%80%81%20%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%95%B0%E6%8D%AE) This section provides an overview of the company's Q1 2024 financial performance, highlighting key accounting data, non-recurring items, and significant changes in financial indicators [Key Accounting Data and Financial Indicators](index=1&type=section&id=%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) The company experienced revenue growth and increased R&D in Q1 2024, but net profit after non-recurring items declined, and operating cash flow significantly deteriorated Q1 2024 Core Financial Indicators | Indicator | Current Period (Yuan) | Year-on-Year Change (%) | | :--- | :--- | :--- | | Operating Revenue | 74,188,129.92 | 9.98% | | Net Profit Attributable to Shareholders | 25,882,628.53 | 8.07% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) | 19,987,027.01 | -12.70% | | Net Cash Flow from Operating Activities | -48,812,416.79 | -4,356.12% | | Basic Earnings Per Share (Yuan/share) | 0.49 | -18.83% | | Total R&D Investment | 9,562,034.25 | 41.95% | | R&D Investment as % of Operating Revenue | 12.89% | Increased by 2.9 percentage points | [Non-recurring Gains and Losses and Amounts](index=2&type=section&id=%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) Non-recurring gains and losses totaled approximately 5.90 million Yuan this quarter, primarily from entrusted investments and government subsidies, significantly boosting net profit Q1 2024 Non-recurring Gains and Losses Items | Item | Amount (Yuan) | | :--- | :--- | | Gains/Losses from entrusted investments or asset management | 4,216,650.68 | | Government subsidies recognized in current profit/loss | 2,660,454.74 | | Gains/Losses from disposal of non-current assets | 47,211.90 | | Other non-operating income and expenses | 11,684.47 | | **Total** | **5,895,601.52** | [Analysis of Major Financial Indicator Changes](index=3&type=section&id=%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87%E5%8F%91%E7%94%9F%E5%8F%98%E5%8A%A8%E7%9A%84%E6%83%85%E5%86%B5%E3%80%81%E5%8E%9F%E5%9B%A0) Significant shifts occurred in financial indicators, including reduced cash, increased receivables, higher R&D, and substantial net cash outflows from operating, investing, and financing activities - Cash and equivalents decreased by **66.20%** year-on-year, while transactional financial assets increased by **37.63%**, primarily due to the company allocating more funds to wealth management products this period[8](index=8&type=chunk) - Accounts receivable increased by **52.86%** year-on-year, mainly because the company proactively extended credit to high-quality distributors this period[8](index=8&type=chunk) - Net cash flow from operating activities sharply decreased by **4,356.12%** year-on-year, primarily due to reduced collections from implementing credit policies for distributors and increased various expenses[9](index=9&type=chunk) - Net cash flow from investing and financing activities significantly decreased by **2,034.51%** and **4,033.45%** respectively, mainly due to increased purchases of wealth management products and the implementation of share repurchases this period[9](index=9&type=chunk) [Shareholder Information](index=4&type=section&id=%E4%BA%8C%E3%80%81%20%E8%82%A1%E4%B8%9C%E4%BF%A1%E6%81%AF) This section details the company's shareholder structure, including the total number of common shareholders and the controlling interests of its largest shareholders [Shareholding Status](index=4&type=section&id=%E6%99%AE%E9%80%9A%E8%82%A1%E8%82%A1%E4%B8%9C%E6%80%BB%E6%95%B0%E5%92%8C%E8%A1%A8%E5%86%B3%E6%9D%83%E6%81%A2%E5%A4%8D%E7%9A%84%E4%BC%98%E5%85%88%E8%82%A1%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E4%B8%9C%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5%E8%A1%A8) The company has 5,338 common shareholders with a concentrated equity structure, controlled by Guo Yijun and Li Daihong through their investment entities - As of the end of the reporting period, the company had **5,338** common shareholders[11](index=11&type=chunk) - The largest shareholder is Chongqing Xishan Investment Co., Ltd., with a **36.06%** stake[12](index=12&type=chunk) - The actual controllers, Guo Yijun and Li Daihong, form a concerted action relationship through Xishan Investment, Tongxin Investment, and Guo Yijun's personal holdings[13](index=13&type=chunk) [Quarterly Financial Statements](index=7&type=section&id=%E5%9B%9B%E3%80%81%20%E5%AD%A3%E5%BA%A6%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This section presents the company's detailed balance sheet, income statement, and cash flow statement for Q1 2024, outlining asset, liability, equity, revenue, expense, and cash flow movements [Balance Sheet](index=7&type=section&id=%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) As of March 31, 2024, total assets decreased by 3.30%, driven by a significant shift from cash to transactional financial assets and a rise in accounts receivable, while liabilities and owners' equity also saw changes Balance Sheet Major Item Changes (March 31, 2024 vs December 31, 2023) | Item | March 31, 2024 (Yuan) | December 31, 2023 (Yuan) | Change (%) | | :--- | :--- | :--- | :--- | | Cash and Equivalents | 240,758,737.62 | 712,248,130.35 | -66.20% | | Transactional Financial Assets | 1,203,052,986.30 | 874,126,267.12 | 37.63% | | Accounts Receivable | 85,076,098.89 | 55,654,940.72 | 52.86% | | Total Assets | 2,241,624,744.02 | 2,318,065,640.21 | -3.30% | | Total Liabilities | 113,885,245.60 | 157,408,345.87 | -27.65% | | Owners' Equity Attributable to Shareholders | 2,127,739,498.42 | 2,160,657,294.34 | -1.52% | [Income Statement](index=9&type=section&id=%E5%88%A9%E6%B6%A6%E8%A1%A8) Q1 2024 saw a 9.98% revenue increase, but rising sales and R&D expenses were offset by reduced financial expenses and non-operating gains, leading to positive operating and net profit growth Income Statement Core Data (Q1 2024 vs Q1 2023) | Item | Q1 2024 (Yuan) | Q1 2023 (Yuan) | Year-on-Year Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 74,188,129.92 | 67,453,654.71 | 9.98% | | Operating Cost | 21,722,939.08 | 20,645,382.34 | 5.22% | | Selling Expenses | 18,060,842.13 | 14,717,186.90 | 22.72% | | R&D Expenses | 9,562,034.25 | 6,736,183.17 | 41.95% | | Financial Expenses | -3,383,257.52 | -617,680.29 | 447.74% | | Operating Profit | 30,163,234.06 | 23,591,211.09 | 27.86% | | Net Profit | 25,882,628.53 | 23,949,631.82 | 8.07% | [Cash Flow Statement](index=11&type=section&id=%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) The company's cash flow significantly worsened this quarter, with substantial net outflows from operating, investing, and financing activities, primarily driven by reduced collections, wealth management purchases, and share repurchases Cash Flow Statement Key Data (Q1 2024 vs Q1 2023) | Item | Q1 2024 (Yuan) | Q1 2023 (Yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -48,812,416.79 | -1,095,402.25 | | Net Cash Flow from Investing Activities | -362,041,326.13 | -16,961,319.37 | | Net Cash Flow from Financing Activities | -60,629,496.71 | -1,466,801.94 | | Net Increase in Cash and Cash Equivalents | -471,489,392.73 | -19,529,188.87 |

证券代码：688576 证券简称：西山科技 公告编号：2024-013 重庆西山科技股份有限公司 2023 年度募集资金存放与实际使用情况的专项报告 | 减：应支付发行费用 | | | | | 1,804.25 | | --- | --- | --- | --- | --- | --- | | 募集资金净额 | | | | 163,152.86 | | | 减：置换预先投入募集资金投资项目的自筹资金 | | | | | 12,824.17 | | 减：募投项目支出金额 | | | | | 8,700.67 | | 减：使用闲置募集资金进行现金管理 | | | | 70,500.00 | | | 减：以超募资金永久补充流动资金 | | | | | 29,000.00 | | 加：累计利息收入和理财收益扣除手续费净额 | | | | | 682.10 | | 加：尚未支付的发行费用 | | | | | 40.80 | | 截至 年 12 日募集资金账户余额 | 2023 | 月 | 31 | 42,850.91 | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的 ...

重庆西山科技股份有限公司 审计委员会对会计师事务所履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治 理准则》《国有企业、上市公司选聘会计师事务所管理办法》等规定和要求， 董事会审计委员会本着勤勉尽责的原则进行履职。现将公司董事会审计委员会 对永拓会计师事务所（特殊普通合伙）（以下简称"永拓会计师事务所"）2023 年度履行监督职责的情况汇报如下： 一、2023 年年审会计师事务所基本情况 永拓会计师事务所成立于 2013 年 12 月 20 日，注册地位于北京市朝阳区关 东店北街 1 号 2 幢 13 层，首席合伙人为吕江。截至 2023 年末，永拓会计师事 务所拥有合伙人 97 人，拥有执业注册会计师 312 人，其中拥有证券相关业务服 务经验的执业注册会计师 300 多人，注册会计师中签署过证券服务业务审计报 告的有 152 人。 2023 年度业务收入总额 35,172 万元 ，其中审计业务收入 29,644 万元、 证券业务收入 14,106 万元。2023 年度 A 股上市公司审计客户共计 34 家，收 费总额 4,329.95 万元。审计客户涉及行业包括化学原 ...

公司代码：688576 公司简称：西山科技 重庆西山科技股份有限公司 2023 年度内部控制评价报告 重庆西山科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内 部控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专 项监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了 评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露 内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责 组织领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内 容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别 及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整， 提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标 提供合理保证。此外，由于情况的变化可 ...

（一） 个人工作履历、专业背景及兼职情况 本人白礼西，中国国籍，无境外永久居留权，1964 年 5 月出生，本科学历， 高级工程师职称，执业药师。1983 年 8 月至 1993 年 11 月就职于涪陵制药厂并 先后担任技术员、副厂长、厂长；1993 年 12 月至 2019 年 6 月就职于太极集团 （600129.SH）并担任董事长、党委书记等职务；2019 年 6 月至 2020 年 11 月担 任重庆市涪陵商务集团有限公司监事会主席；2016 年至 2023 年 4 月担任重庆医 药行业协会会长；2020 年 11 月至今担任重庆大易科技投资有限公司董事长。 2021 年 12 月至今担任公司独立董事。 （二） 是否存在影响独立性的情况说明 作为公司的独立董事，本人未在公司担任除独立董事以外的任何职务，也未 在公司主要股东处担任任何职务，与公司以及公司主要股东之间不存在妨碍本人 进行独立客观判断的关系，不存在影响独立董事独立性的情况。 二、 独立董事年度履职概况 （一）出席会议情况 重庆西山科技股份有限公司 2023 年度独立董事述职报告 本人作为重庆西山科技股份有限公司（以下简称"西山科技"或"公司 ...

关于重庆西山科技股份有限公司 2023年度募集资金存放与使用情况 专项报告的鉴证报告 永证专字（2024）第 310116 号 关于重庆西山科技股份有限公司 2023年度募集资金存放与使用情况 专项报告的鉴证报告 目 录 永拓会计师事务所（特殊普通合伙） 一、关于重庆西山科技股份有限公司2023年度募集资金存放 与使用专项报告的鉴证报告 二、重庆西山科技股份有限公司2023年度募集资金存放 与使用情况专项报告 重庆西山科技股份有限公司全体股东： 我们鉴证了后附的重庆西山科技股份有限公司(以下简称"西山科技")董事 会编制的《2023 年度募集资金存放与使用情况专项报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供西山科技年度报告披露时使用,不得用作任何其他目的。我 们同意将本鉴证报告作为西山科技年度报告的必备文件,随同其他文件一起报送 并对外披露。 二、董事会的责任 西山科技董事会的责任是按照《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》（证监会公告[2022]15 号）《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》及相关格式指引的 ...

Financial Performance - In 2023, the company achieved operating revenue of CNY 360.69 million, an increase of 37.52% compared to the previous year[23]. - The net profit attributable to shareholders of the listed company was CNY 117.34 million, reflecting a growth of 55.73% year-on-year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 92.48 million, up 40.40% from the previous year[23]. - The company's cash flow from operating activities decreased by 13.93% year-on-year, primarily due to credit policies implemented for distributors[24]. - The company's total assets increased by 343.51% year-on-year, reaching CNY 2.32 billion, mainly due to the influx of funds from a public stock issuance[24]. - The basic earnings per share rose to CNY 2.53, a 33.16% increase from the previous year[23]. - The company reported a total revenue of 7,100 million RMB for the year, with a net profit of 4,650.38 million RMB, representing a growth of approximately 6.5% compared to the previous year[80]. Research and Development - Research and development expenses accounted for 12.89% of operating revenue, an increase of 1.47 percentage points compared to the previous year[23]. - The number of R&D personnel increased by 21% in 2023, emphasizing the company's commitment to innovation[36]. - The company submitted 241 patent applications during the reporting period, including 24 invention patents[37]. - The company has developed advanced medical micro-motor technology with a speed range of 15,000rpm to 65,000rpm, enhancing performance and reliability[70]. - The company has achieved a significant increase in the number of patent applications, with a total of 1,556 applications filed, including 248 in the current year[71]. - The company is expanding its product offerings in minimally invasive surgical solutions, focusing on neurosurgery, orthopedics, ENT, and breast surgery[76]. Market and Sales Strategy - The company is actively expanding its market presence by leveraging post-pandemic surgical demand recovery and targeting differentiated marketing strategies[41]. - The company has established a strong presence in the minimally invasive surgical tools market, which is expected to grow significantly due to advancements in technology and materials[51]. - The company has established a distribution network in over 40 countries and regions, with plans to enhance international certifications and partnerships with major medical device companies[137]. - The company is focused on building a comprehensive marketing network and enhancing brand recognition through academic conferences and clinical training[136]. Corporate Governance - The company emphasizes transparency by disclosing significant information accurately and timely, protecting the interests of minority investors[143]. - The company has established a comprehensive corporate governance system, including rules for shareholder meetings, board meetings, and supervisory meetings[141]. - The board of directors convened 14 meetings in 2023, ensuring adherence to legal and regulatory requirements throughout the decision-making process[142]. - The company has not encountered any significant discrepancies with the regulations set by the China Securities Regulatory Commission regarding corporate governance[143]. Risk Management - The company faces risks from intensified market competition, particularly from established international brands, which may impact sales growth and market share if it fails to maintain product quality and innovation[91]. - The company is at risk of project halts or new product failures due to high investment and uncertainty in the medical device industry, which could affect its future profitability[92]. - The company’s products are subject to strict regulatory oversight, with risks associated with product registration and renewal processes[95]. Employee and Talent Management - The company has a competitive compensation policy to attract local talent, with different incentive structures based on job categories and levels[172]. - The company has implemented an annual training plan to enhance employee skills and align with strategic goals, increasing the training budget each year[173]. - The total compensation for R&D personnel reached 2,386.44 million RMB, with an average salary of 19.72 million RMB, reflecting an increase from 1,701.30 million RMB and 17.01 million RMB respectively[83]. Dividend and Financial Policy - The company plans to distribute a cash dividend of 10.0 yuan per 10 shares, totaling approximately 52.35 million yuan, which accounts for 44.62% of the net profit attributable to shareholders for 2023[5]. - The company has established a cash dividend policy that requires a minimum of 30% of the average distributable profit over the first three years post-IPO to be distributed in cash[176]. - The company has no major external investment plans or significant cash expenditures anticipated in the next twelve months, allowing for the proposed cash dividend distribution[175]. Environmental and Social Responsibility - The company invested 2.5 million yuan in environmental protection during the reporting period[185]. - The company has actively participated in social welfare activities, donating a total of 200,000 yuan to educational foundations over two years[192]. - The company emphasizes ESG responsibilities, enhancing management levels and maintaining good communication with stakeholders[184].

重庆西山科技股份有限公司 非经营性资金占用及其他关联资金往来情况 专项审计说明 永拓会计师事务所（特殊普通合伙） 重庆西山科技股份有限公司 非经营性资金占用及其他关联资金往来情况 专项审计说明 永证专字（2024）第310115号 重庆西山科技股份有限公司全体股东： 我们接受委托，依据《中国注册会计师执业准则》审计了重庆西山科技股份 有限公司（以下简称"西山科技"）2023年度财务报表，包括2023年12月31日的 资产负债表，2023年度的利润表、现金流量表、股东权益变动表以及财务报表附 注，并出具了无保留意见的审计报告。在此基础上，我们审计了后附的西山科技 管理层编制的2023年度《非经营性资金占用及其他关联资金往来情况汇总表》（以 下简称"汇总表"）。 一、对报告使用者和使用目的的限定 本报告仅供西山科技年度报告披露时使用，不得用作任何其他目的。我们同 意将本报告作为西山科技年度报告的必备文件，随同其他文件一起报送并对外披 露。 为了更好地理解西山科技2023年度非经营性资金占用及其他关联资金往来 情况，汇总表应当与已审的财务报表一并阅读。 二、管理层的责任 西山科技管理层的责任是提供真实、合法、完整的 ...

东方证券承销保荐有限公司 关于重庆西山科技股份有限公司 2023 年度持续督导工作现场检查报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律、法规 要求，东方证券承销保荐有限公司（以下简称"东方投行"或"保荐机构"）作 为重庆西山科技股份有限公司（以下简称"西山科技"或"公司"）首次公开发 行股票并持续督导的保荐机构，对公司 2023 年度（以下简称"本持续督导期间"） 的规范运作情况进行了现场检查，现就现场检查的有关情况报告如下： 一、本次现场检查的基本情况 （一）保荐机构 东方证券承销保荐有限公司 （二）保荐代表人 杨振慈、吴其明 （三）现场检查时间 保荐机构现场检查人员分别在 2023 年 12 月 27 日至 12 月 29 日、2024 年 1 月 8 日至 1 月 10 日、2024 年 1 月 22 日至 1 月 25 日、2024 年 3 月 13 日至 3 月 14 日、2024 年 3 月 25 日至 3 月 29 日对公 ...

重庆西山科技股份有限公司 审 计 报 告 目 录 永拓会计师事务所（特殊普通合伙） 一、审计报告 二、财务报表 1．2023 年 12 月 31 日资产负债表 2．2023 年度利润表 3．2023 年度现金流量表 4．2023 年度股东权益变动表 5．2023 年度财务报表附注 审 计 报 告 永证审字（2024）第110017号 重庆西山科技股份有限公司全体股东： 一、审计意见 我们审计了重庆西山科技股份有限公司（以下简称"西山科技"）财务报表， 包括 2023 年 12 月 31 日的资产负债表，2023 年度的利润表、现金流量表和股东 权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制， 公允反映了西山科技 2023 年 12 月 31 日的财务状况以及 2023 年度的经营成果和 现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注 册会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。 按照中国注册会计师职业道德守则，我们独立于西山科技，并履行了职业道德方 面的其他责任。我们相信，我们 ...